Gene · 5890
Papers1,861
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,861
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CRISPR-Cas12a REC2-Nuc interactions drive target-strand cleavage and constrain trans cleavage. | Nucleic Acids Res | 2025 | 41063348 | PubTator, text mining | PubMed |
| And… cut! - how conformational regulation of CRISPR-Cas effectors directs nuclease activity. | Biochem J | 2025 | 40996239 | PubTator, text mining | PubMed |
Complete remission with olaparib in BRIP1-mutated metastatic high-grade pleomorphic sarcoma: case study and literature review - an example of a genomic profiling-based tumor treatment, in a cancer type with high unmet clinical need. | Acta Oncol | 2025 | 40988318 | PubTator, text mining | PubMed |
| AsCas12a tolerates insertions in target DNA. | Nucleic Acids Res | 2025 | 40966510 | PubTator, text mining | PubMed |
| Potential role of Fanconi anemia pathway in the pathogenesis of endometrial cancer (Review). | Mol Med Rep | 2025 | 40849815 | PubTator, text mining | PubMed |
| Discovery of CRISPR-Cas12a clades using a large language model. | Nat Commun | 2025 | 40849498 | PubTator, text mining | PubMed |
| The distinct landscape of tumor immune microenvironment in homologous recombination deficient cancers. | Biomark Res | 2025 | 40830526 | PubTator, text mining | PubMed |
| TSC2-mutated perivascular epithelioid cell tumor with partial response to mTOR inhibition: a case report and literature review. | Discov Oncol | 2025 | 40739411 | PubTator, text mining | PubMed |
| A systems-based approach to uterine fibroids identifies differential splicing associated with abnormal uterine bleeding. | Commun Med (Lond) | 2025 | 40739398 | PubTator, text mining | PubMed |
| LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. | JCO Precis Oncol | 2025 | 40632975 | PubTator, text mining | PubMed |
| High burden of variants of uncertain significance in early-onset colorectal cancer among indigenous African patients: a call for global research equity in cancer genetics. | Mol Biol Rep | 2025 | 40627234 | PubTator, text mining | PubMed |
| A rational engineering strategy for structural dynamics modulation enables target specificity enhancement of the Cas9 nuclease. | Nucleic Acids Res | 2025 | 40539512 | PubTator, text mining | PubMed |
| Bioprospecting potential genetic biomarkers of gallbladder cancer. | Mol Biol Rep | 2025 | 40439781 | PubTator, text mining | PubMed |
| Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers. | Oncologist | 2025 | 40421962 | PubTator, text mining | PubMed |
| Case Studies of Orphan Domain Reclassification in ECOD by Expert Curation. | Proteins | 2025 | 40418090 | PubTator, text mining | PubMed |
| Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers. | NPJ Precis Oncol | 2025 | 40369102 | PubTator, text mining | PubMed |
| CD34-positive pleomorphic uterine sarcoma with NUDT3::RAD51B fusion. | Virchows Arch | 2025 | 40360859 | PubTator, text mining | PubMed |
| A GWAS of angiotensin-converting enzyme inhibitor-induced angioedema in a South African population. | J Allergy Clin Immunol Glob | 2025 | 40290521 | PubTator, text mining | PubMed |
| Biochemical Mechanisms of Genetic Recombination and DNA Repair. | Annu Rev Biochem | 2025 | 40153609 | PubTator, text mining | PubMed |
| Daxx Variation as a Potential Predictive Marker of the Therapeutic Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. | Cancer Med | 2025 | 40130316 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5890/papers?page=3